查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1621513

治疗诊断学市场：按产品、应用和最终用户划分 - 全球预测 2025-2030

Theranostics Market by Product (Product, Services, Software), Application (Bone Metastatis, Cardiovascular Diseases, Lymphoma), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023 年治疗诊断学市场价值为 23.3 亿美元，预计到 2024 年将达到 26.7 亿美元，复合年增长率为 14.89%，到 2030 年将达到 61.8 亿美元。

治疗诊断学是治疗学和诊断学的组合，代表了个人化医疗的重大进步，旨在提供标靶治疗策略，同时透过诊断测试监测治疗效果。这两种方法满足了针对个别患者情况进行更精确的医疗干预的需求，改善治疗结果并最大限度地减少副作用。治疗诊断学学应用主要涵盖肿瘤学、心臟科和神经学，最终用途是医院、诊断实验室和专科诊所。影响市场成长的关键因素包括基因组学和精准医学的进步、慢性病盛行率的增加以及对个人化治疗的需求不断增长。人工智慧和机器学习的整合存在新的潜在机会，可以提高诊断准确性并简化治疗监测。然而，高昂的开发成本、复杂的监管障碍和有限的报销框架等限制为市场扩张带来了挑战。此外，创新常常受到智慧财产权问题和需要可靠的临床证据来支持治疗诊断方法有效性的阻碍。儘管存在这些挑战，该市场仍为创新提供了肥沃的土壤，特别是在开发多模态成像剂、增强放射性药物应用以及探索各种疾病的新型生物标记方面。公司可以透过投资研发合作、专注于具有成本效益的解决方案以及倡导有利的监管政策来促进成长。在技​​术进步和对个人化医疗策略的日益重视的推动下，市场动态正在动态发展。希望利用这一趋势的公司优先考虑对新技术的敏捷反应，与学术机构建立伙伴关係以扩大研究，并参与策略行销以改善医疗保健专业人员和患者之间的关係。的认识与教育。这些策略将帮助我们克服挑战并在这个快速发展的领域中建立强大的地位。

主要市场统计
基准年[2023] 23.3亿美元
预计年份 [2024] 26.7亿美元
预测年份 [2030] 61.8亿美元
复合年增长率（%） 14.89%

市场动态：揭示快速发展的治疗诊断学市场的关键市场洞察

供需的动态交互作用正在改变治疗诊断学市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 目标疾病的全球盛行率
    • 个人化医疗与分子生物学的不断进步
  • 市场限制因素
    • 研发高成本、监理核准复杂
  • 市场机会
    • 治疗诊断学中资料分析和机器学习的进一步整合
    • 扩大新生物标记和非侵入性成像技术的开发
  • 市场挑战
    • 资料隐私和个人化医疗的伦理考量

波特的五力：驾驭治疗诊断学市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解治疗诊断学市场的外部影响

外部宏观环境因素在塑造治疗诊断学市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解治疗诊断学市场的竞争格局

对治疗诊断学市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵治疗诊断学市场供应商绩效评估

FPNV定位矩阵是评估治疗诊断学市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了治疗诊断学市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对治疗诊断学市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开发：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球目标疾病的盛行率正在增加
      • 个人化医疗与分子生物学的进展
    • 抑制因素
      • 研发成本高、监理核准复杂
    • 机会
      • 治疗诊断学中资料分析和机器学习的增强集成
      • 新生物标记和非侵入性成像技术的开发仍在继续
    • 任务
      • 资料隐私和个人化医疗的伦理考量
  • 市场区隔分析
    • 产品：更多地使用软体进行资料收集、处理和分析
    • 最终使用者：扩大医院治疗治疗诊断学在各种疾病管理的潜力
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章治疗诊断学市场：副产品

  • 产品
    • 诊断影像
      • 功能性影像
      • 分子影像
      • 核子造影
    • 体外诊断/生物标记筛检
      • 萤光原位杂合反应
      • 次世代定序
      • 聚合酵素链锁反应
    • 放射性药物
      • 氟18
      • 镓68
      • 碘131
      • 镏177
      • 镭223
      • 钐153
      • 锶89
      • Technetium99
      • 钇90
  • 服务
  • 软体
    • 影像分析
    • 预测模型

第七章治疗诊断学市场：依应用分类

  • 骨转移
  • 心血管疾病
  • 淋巴瘤
  • 神经内分泌肿瘤
  • 摄护腺癌

第八章治疗诊断学市场：依最终使用者分类

  • 癌症护理中心
  • 医院
  • 研究学术中心
  • 治疗诊断学中心

第九章美洲的治疗诊断学市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太治疗诊断学市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的治疗诊断学市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Clarity 的前列腺癌药物临床试验取得最高剂量水平队列进展
    • BAMF Health 和 GE Healthcare 合作，为治疗诊断学的发展提供永续、可扩展的解决方案
    • 加州大学洛杉矶分校健康中心开设治疗诊断学中心
  • 战略分析和建议

公司名单

  • Actinium Pharmaceuticals, Inc.
  • Ariceum Therapeutics GmbH
  • Astellas Pharma Inc.
  • BAMF Health
  • Bayer AG
  • bioMerieux SA
  • Biosynth Ltd.
  • Cardinal Health, Inc.
  • Cerebral Therapeutics, Inc.
  • Clarity Pharmaceuticals
  • Curasight A/S
  • Curium Inc.
  • Evergreen Theragnostics, Inc.
  • GE HealthCare Technologies, Inc.
  • Hermes Medical Solutions AB
  • Icon Group
  • Indi Molecular, Inc.
  • Integrated Clinical Oncology Network Pty Ltd.
  • Invicro, LLC
  • Ipsen Pharma
  • Radiopharm Theranostics Limited
  • Ratio Therapeutics
  • Siemens Healthineers AG
  • SOFIE Co.
  • Telix Pharmaceuticals Limited
  • United Theranostics
Product Code: MRR-61081604A0A5

The Theranostics Market was valued at USD 2.33 billion in 2023, expected to reach USD 2.67 billion in 2024, and is projected to grow at a CAGR of 14.89%, to USD 6.18 billion by 2030.

Theranostics, a portmanteau of therapeutics and diagnostics, represents a significant advancement in personalized medicine, aiming to offer targeted treatment strategies while simultaneously monitoring the therapy's efficacy through diagnostic tests. This dual approach addresses the necessity for more precise medical interventions tailored to individual patient profiles, improving treatment outcomes and minimizing adverse effects. The application of theranostics predominantly spans oncology, cardiology, and neurology, with end-use extending across hospital settings, diagnostic laboratories, and specialty clinics. Key factors influencing market growth include advancements in genomics and precision medicine, increasing prevalence of chronic diseases, and rising demand for personalized treatments. The latest potential opportunities exist in the integration of artificial intelligence and machine learning to enhance diagnostic accuracy and streamline therapeutic monitoring. However, limitations such as high development costs, complex regulatory hurdles, and limited reimbursement frameworks pose challenges to market expansion. Furthermore, technological innovations are often impeded by intellectual property issues and a need for robust clinical evidence to support the efficacy of theranostic approaches. Despite these challenges, the market offers fertile ground for innovation, particularly in developing multimodal imaging agents, enhancing radiopharmaceutical applications, and exploring novel biomarkers for various diseases. Businesses can foster growth by investing in R&D collaborations, focusing on cost-effective solutions, and advocating for favorable regulatory policies. The nature of the theranostics market is dynamic and evolving, driven by technological advancements and an increasing emphasis on personalized care strategies. Companies looking to capitalize on this trend should prioritize agile adaptation to emerging technologies, foster partnerships with academic institutions for research expansion, and engage in strategic marketing to enhance awareness and education about theranostics' benefits among healthcare professionals and patients alike. These strategies can help navigate the challenges and position businesses to ground themselves firmly in this burgeoning field.

KEY MARKET STATISTICS
Base Year [2023] USD 2.33 billion
Estimated Year [2024] USD 2.67 billion
Forecast Year [2030] USD 6.18 billion
CAGR (%) 14.89%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Theranostics Market

The Theranostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of target diseases globally
    • Rising advancements in personalized medicine and molecular biology
  • Market Restraints
    • High costs associated with R&D and the complexity of regulatory approvals
  • Market Opportunities
    • Increasing integration of data analytics and machine learning in theranostics
    • Growing development of novel biomarkers and non-invasive imaging techniques
  • Market Challenges
    • Data privacy and the ethical considerations of personalized medicine

Porter's Five Forces: A Strategic Tool for Navigating the Theranostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Theranostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Theranostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Theranostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Theranostics Market

A detailed market share analysis in the Theranostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Theranostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Theranostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Theranostics Market

A strategic analysis of the Theranostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Theranostics Market, highlighting leading vendors and their innovative profiles. These include Actinium Pharmaceuticals, Inc., Ariceum Therapeutics GmbH, Astellas Pharma Inc., BAMF Health, Bayer AG, bioMerieux SA, Biosynth Ltd., Cardinal Health, Inc., Cerebral Therapeutics, Inc., Clarity Pharmaceuticals, Curasight A/S, Curium Inc., Evergreen Theragnostics, Inc., GE HealthCare Technologies, Inc., Hermes Medical Solutions AB, Icon Group, Indi Molecular, Inc., Integrated Clinical Oncology Network Pty Ltd., Invicro, LLC, Ipsen Pharma, Radiopharm Theranostics Limited, Ratio Therapeutics, Siemens Healthineers AG, SOFIE Co., Telix Pharmaceuticals Limited, and United Theranostics.

Market Segmentation & Coverage

This research report categorizes the Theranostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Product, Services, and Software. The Product is further studied across Diagnostic Imaging, In Vitro Diagnostics/Biomarker Screening, and Radiopharmaceuticals. The Diagnostic Imaging is further studied across Functional Imaging, Molecular Imaging, and Nuclear Imaging. The In Vitro Diagnostics/Biomarker Screening is further studied across Fluorescence In Situ Hybridization, Next-generation Sequencing, and Polymerase Chain Reaction. The Radiopharmaceuticals is further studied across Fluorine-18, Gallium-68, lodine-131, Lutetium-177, Radium-223, Samarium-153, Strontium-89, Technetium-99, and Yttrium-90. The Software is further studied across Imaging Analytics and Predictive Modeling.
  • Based on Application, market is studied across Bone Metastatis, Cardiovascular Diseases, Lymphoma, Neuroendocrine Tumors, and Prostate Cancer.
  • Based on End-User, market is studied across Cancer Care Centers, Hospitals, Research & Academic Centers, and Theranostics Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of target diseases globally
      • 5.1.1.2. Rising advancements in personalized medicine and molecular biology
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with R&D and the complexity of regulatory approvals
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing integration of data analytics and machine learning in theranostics
      • 5.1.3.2. Growing development of novel biomarkers and non-invasive imaging techniques
    • 5.1.4. Challenges
      • 5.1.4.1. Data privacy and the ethical considerations of personalized medicine
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising usage of software for data acquisition, processing, and analysis
    • 5.2.2. End-User: Growing potential of theranostics among hospitals for the management of a variety of diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Theranostics Market, by Product

  • 6.1. Introduction
  • 6.2. Product
    • 6.2.1. Diagnostic Imaging
      • 6.2.1.1. Functional Imaging
      • 6.2.1.2. Molecular Imaging
      • 6.2.1.3. Nuclear Imaging
    • 6.2.2. In Vitro Diagnostics/Biomarker Screening
      • 6.2.2.1. Fluorescence In Situ Hybridization
      • 6.2.2.2. Next-generation Sequencing
      • 6.2.2.3. Polymerase Chain Reaction
    • 6.2.3. Radiopharmaceuticals
      • 6.2.3.1. Fluorine-18
      • 6.2.3.2. Gallium-68
      • 6.2.3.3. lodine-131
      • 6.2.3.4. Lutetium-177
      • 6.2.3.5. Radium-223
      • 6.2.3.6. Samarium-153
      • 6.2.3.7. Strontium-89
      • 6.2.3.8. Technetium-99
      • 6.2.3.9. Yttrium-90
  • 6.3. Services
  • 6.4. Software
    • 6.4.1. Imaging Analytics
    • 6.4.2. Predictive Modeling

7. Theranostics Market, by Application

  • 7.1. Introduction
  • 7.2. Bone Metastatis
  • 7.3. Cardiovascular Diseases
  • 7.4. Lymphoma
  • 7.5. Neuroendocrine Tumors
  • 7.6. Prostate Cancer

8. Theranostics Market, by End-User

  • 8.1. Introduction
  • 8.2. Cancer Care Centers
  • 8.3. Hospitals
  • 8.4. Research & Academic Centers
  • 8.5. Theranostics Centers

9. Americas Theranostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Theranostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Theranostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Clarity's Theranostic Prostate Cancer Trial Progresses at the Highest Dose Level Cohort
    • 12.3.2. BAMF Health and GE HealthCare Collaborate to Enable Sustainable and Scalable Solutions for Growth in Theranostics
    • 12.3.3. UCLA Health to Open Theranostics Center
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Actinium Pharmaceuticals, Inc.
  • 2. Ariceum Therapeutics GmbH
  • 3. Astellas Pharma Inc.
  • 4. BAMF Health
  • 5. Bayer AG
  • 6. bioMerieux SA
  • 7. Biosynth Ltd.
  • 8. Cardinal Health, Inc.
  • 9. Cerebral Therapeutics, Inc.
  • 10. Clarity Pharmaceuticals
  • 11. Curasight A/S
  • 12. Curium Inc.
  • 13. Evergreen Theragnostics, Inc.
  • 14. GE HealthCare Technologies, Inc.
  • 15. Hermes Medical Solutions AB
  • 16. Icon Group
  • 17. Indi Molecular, Inc.
  • 18. Integrated Clinical Oncology Network Pty Ltd.
  • 19. Invicro, LLC
  • 20. Ipsen Pharma
  • 21. Radiopharm Theranostics Limited
  • 22. Ratio Therapeutics
  • 23. Siemens Healthineers AG
  • 24. SOFIE Co.
  • 25. Telix Pharmaceuticals Limited
  • 26. United Theranostics

LIST OF FIGURES

  • FIGURE 1. THERANOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. THERANOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THERANOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. THERANOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. THERANOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THERANOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THERANOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THERANOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THERANOSTICS MARKET SIZE, BY FUNCTIONAL IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THERANOSTICS MARKET SIZE, BY MOLECULAR IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THERANOSTICS MARKET SIZE, BY NUCLEAR IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THERANOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THERANOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THERANOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL THERANOSTICS MARKET SIZE, BY FLUORINE-18, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL THERANOSTICS MARKET SIZE, BY GALLIUM-68, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL THERANOSTICS MARKET SIZE, BY LODINE-131, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL THERANOSTICS MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL THERANOSTICS MARKET SIZE, BY RADIUM-223, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL THERANOSTICS MARKET SIZE, BY SAMARIUM-153, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL THERANOSTICS MARKET SIZE, BY STRONTIUM-89, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL THERANOSTICS MARKET SIZE, BY TECHNETIUM-99, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL THERANOSTICS MARKET SIZE, BY YTTRIUM-90, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL THERANOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL THERANOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL THERANOSTICS MARKET SIZE, BY IMAGING ANALYTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL THERANOSTICS MARKET SIZE, BY PREDICTIVE MODELING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL THERANOSTICS MARKET SIZE, BY BONE METASTATIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL THERANOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL THERANOSTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL THERANOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL THERANOSTICS MARKET SIZE, BY CANCER CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL THERANOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL THERANOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL THERANOSTICS MARKET SIZE, BY THERANOSTICS CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. JAPAN THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. MALAYSIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 149. MALAYSIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. PHILIPPINES THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 158. PHILIPPINES THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. SINGAPORE THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. SINGAPORE THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 165. SINGAPORE THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 166. SINGAPORE THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 167. SINGAPORE THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH KOREA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH KOREA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH KOREA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. TAIWAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. TAIWAN THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 181. TAIWAN THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 182. TAIWAN THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 183. TAIWAN THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 184. TAIWAN THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. TAIWAN THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. THAILAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. THAILAND THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 189. THAILAND THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 190. THAILAND THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 191. THAILAND THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 192. THAILAND THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. THAILAND THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 195. VIETNAM THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 196. VIETNAM THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 197. VIETNAM THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 198. VIETNAM THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 199. VIETNAM THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 200. VIETNAM THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. VIETNAM THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. DENMARK THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. DENMARK THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 214. DENMARK THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 215. DENMARK THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 216. DENMARK THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 217. DENMARK THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. DENMARK THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 220. EGYPT THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. EGYPT THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 222. EGYPT THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 223. EGYPT THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 224. EGYPT THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 225. EGYPT THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. EGYPT THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. FINLAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 229. FINLAND THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 230. FINLAND THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 231. FINLAND THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 232. FINLAND THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 233. FINLAND THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 234. FINLAND THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 236. FRANCE THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. FRANCE THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 238. FRANCE THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 239. FRANCE THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 240. FRANCE THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 241. FRANCE THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. FRANCE THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 244. GERMANY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 245. GERMANY THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 246. GERMANY THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 247. GERMANY THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 248. GERMANY THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 249. GERMANY THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 250. GERMANY THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 252. ISRAEL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 253. ISRAEL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 254. ISRAEL THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 255. ISRAEL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 256. ISRAEL THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 257. ISRAEL THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 258. ISRAEL THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 260. ITALY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 261. ITALY THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 262. ITALY THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 263. ITALY THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 264. ITALY THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 265. ITALY THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. ITALY THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 268. NETHERLANDS THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 270. NETHERLANDS THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 272. NETHERLANDS THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 274. NETHERLANDS THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 276. NIGERIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 277. NIGERIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 278. NIGERIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 279. NIGERIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 280. NIGERIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 281. NIGERIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 282. NIGERIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 284. NORWAY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 285. NORWAY THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 286. NORWAY THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 287. NORWAY THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 288. NORWAY THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 289. NORWAY THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 290. NORWAY THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 292. POLAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 293. POLAND THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 294. POLAND THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 295. POLAND THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 296. POLAND THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 297. POLAND THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 298. POLAND THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 300. QATAR THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 301. QATAR THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 302. QATAR THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 303. QATAR THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 304. QATAR THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 305. QATAR THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 306. QATAR THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 308. RUSSIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 309. RUSSIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 310. RUSSIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 311. RUSSIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 312. RUSSIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 313. RUSSIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 314. RUSSIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 316. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 318. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 320. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 322. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 324. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 326. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 328. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 330. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 332. SPAIN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 333. SPAIN THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 334. SPAIN THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 335. SPAIN THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 336. SPAIN THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 337. SPAIN THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 338. SPAIN THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 340. SWEDEN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 341. SWEDEN THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 342. SWEDEN THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 343. SWEDEN THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 344. SWEDEN THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 345. SWEDEN THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 346. SWEDEN THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 348. SWITZERLAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 350. SWITZERLAND THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 352. SWITZERLAND THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 353. SWITZERLAND THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 354. SWITZERLAND THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 355. TURKEY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 356. TURKEY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 357. TURKEY THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 358. TURKEY THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 359. TURKEY THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 360. TURKEY THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 361. TURKEY THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 362. TURKEY THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 364. UNITED ARAB EMIRATES THERANOSTICS